Abstract. The effects of amrubicin (AMR) and its active metabolite, amrubicinol (AMROH), on the sensitivity of human lung adenocarcinoma A549 cells to ionizing radiation were investigated in vitro. Further, the kinetics of apoptosis and necrosis induction were also analyzed. The cytocidal effects of X-ray irradiation on A549 cells resulted in a low level of radiosensitivity with a D 0 value of 12 Gy. The slopes of the survival curves in the exponential phase were plotted on semilogarithmic paper for radiation combined with AMR (2.5 μg/ml) and AMROH (0.02 μg/ml) treatment, and were shown to be approximately parallel to treatment with irradiation alone. The initial shoulder-shape portion of the survival curve for radiation alone, indicating the repair of sublethal damage, was reduced as compared to that for sequential combined treatment with AMR or AMROH. Sequential treatments with AMR or AMROH prior to ionizing radiation resulted in an additive radio-enhancement effect that reduced not only survival, but also the shoulder width. Fractionated irradiation with 2 Gy per fraction of A549 cells was carried out in vitro similar to that commonly performed in clinical radiotherapy and the radio-resistance of the cells was shown to be inhibited by AMR and AMROH. Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors. The effects of these 4 agents on cells that received X-ray irradiation were compared and all of the agents exhibited comparable radio-enhancement effects. The induction of apoptosis was investigated at 48 and 72 h after administration of AMROH, radiation or combined treatment, and apoptosis was not significantly induced after any of the treatments. We also examined the induction of necrosis, and found that the incidence of necrosis following combined treatment was approximately 2 times higher than that with either of the single treatments.
Introduction
Amrubicin hydrochloride (AMR), an anthracycline derivative (1,2), exhibits antitumor effects by inhibiting topoisomerase II activity and suppressing DNA synthesis (3, 4) . AMR is metabolized to amrubicinol (AMROH) in vivo and has antitumor activity against human non-small cell lung, small cell lung, and superficial bladder cancer, with anticancer effects that range from 10-100 times greater than AMR (5-7). There appears to be a unique correlation between the sensitivity to ionizing radiation and to topoisomerase II inhibitors, which stabilize the cleavable complex between the enzymes and DNA (8) .
Previous reports have clarified that human lung adenocarcinoma A549 cells are radio-or thermo-resistant (9) (10) (11) (12) (13) and have a mutated K-ras gene (14, 15) and wild-type p53 gene (15, 16) . When DNA is damaged, wild-type p53 protein is activated by a phosphorylation signaling pathway, after which it exhibits antitumor effects by inducing either apoptosis or G 1 arrest (17) (18) (19) (20) (21) (22) . In several studies of cultured cells, it has also been found that cells with wild-type p53 are more radiosensitive than cells with mutant p53 (23) (24) (25) (26) . The ras gene was one of the first oncogenes discovered and is known to be involved in cellular proliferation and differentiation (27) (28) (29) . We previously reported that the surviving fractions (SFs) prior to treatment with AMR or AMROH before exposure to 44˚C hyperthermia using the A549 cell line showed an additive thermo-enhancement effect due to inhibition of the repair of sublethal thermal damage (SLTDR) exhibited during the early stages of hyperthermia (13) . We also reported that AMR and AMROH did not elicit cell phase responses, irrespective of the concentration of chemicals, and that the cytotoxicity of pretreatment with AMROH during hyperthermia against A549 cells with wild-type p53 was due to increased necrosis, not apoptosis (13) .
In the present study, we analyzed the effects of modification of AMR and AMROH by X-ray irradiation at the kinetic and molecular levels on the sensitivity of A549 cells with the above-mentioned genetic backgrounds. The SFs of cells treated with X-rays alone showed radio-tolerance due to the repair of sublethal damage (SLDR), which was demonstrated by a so-called shoulder-shaped portion in the initial slope of the survival curve plotted on plotting paper (30) . In this study, we examined the effects of radio-enhancement by AMR and AMROH on the sensitivity of A549 cells to X-rays and compared them with the effects of 2 other DNA topoisomerase II inhibitors, ADM and VP-16. Clinical radiotherapy is generally treated by small-dose fractionated irradiation. In fundamental studies of fractionated irradiation, variations of surviving fractions by SLDR and cellular redistribution following the second irradiation with various interval periods between the 2 exposures have been found (31, 32) . It was also reported that the response of A549 cells in vitro to fractionated irradiation with interval periods of 8-10 h between fractionated doses is required to obtain maximum SLDR (33) .
In the present experiments, treatments of 2 Gy were performed on 4 fractions with a 24 h interval to elucidate the effects of clinical conventional fractionated irradiation. We also analyzed the sensitivity of A549 cells treated with AMR or AMROH for 3 h prior to X-ray irradiation by colonial SFs. As a result, the survival curves of cells treated with fractionated X-ray irradiation following administration with AMR and AMROH demonstrated inhibition of the amount of SLDR by both chemicals, which demonstrated synergistic radioenhancement effects that were significant in comparison with single fractionated irradiation.
DNA damaging agents such as topoisomerase II inhibitors, e.g. etoposide (VP-16) and doxorubicin (adriamycin), lead to double-strand breaks and cell death via apoptosis (34) . A previous study of a topoisomerase II inhibitor showed that it mediated DNA damage by adriamycin and other related antitumor drugs (35) and modified damage caused by X-ray irradiation damage (36, 37) . In the present study, we investigated the induction of apoptosis (38, 39) and necrosis (40, 41) in A549 cells with the wild-type p53 gene and mutant K-ras, which were treated with AMROH for 4 h following X-ray irradiation of 6 Gy.
Materials and methods
Cells and culture medium. The A549 cell line, from a human lung adenocarcinoma (42, 43) , was cultured in Eagle's minimum essential medium (Nissui Pharmaceutical, Tokyo, Japan) containing NCTC-135 (Gibco Laboratories, Grand Island, NY, USA), lactalbumin hydrolysate solution (Difco Laboratories, Detroit, USA), and 15% newborn calf serum (Gibco) (hereafter referred to as MLN-15).
Chemicals, X-ray irradiation and treatments. AMR and AMROH (Sumitomo Pharmaceuticals Co. Ltd., Osaka, Japan) were dissolved separately in culture medium to an appropriate final concentration prior to treatment of the cells. Adhered A549 cells in flasks were treated with AMR or AMROH by replacement of MLN-15 with 6 ml of the agent for various time periods. After exposure to AMR or AMROH, the adhered cells were chased, then gently rinsed twice and re-fed with 6 ml of MLN-15. Thereafter, the treated flasks were incubated stationary in a 5% CO 2 incubator at 37˚C (BNA-111B; Tabai Espec. Co. Ltd., Osaka, Japan) until visible colony formation. Irradiation was carried out using High Technical System X-ray apparatus (HW-150; Hitex Co. Ltd., Tokyo, Japan), with the following settings: 130 kVp, 5 mA, 0.5-mm aluminum filter, dose rate of 1.0 Gy/min.
For combined treatment, chemotherapy and radiotherapy were performed sequentially. Cells treated with AMR or AMROH for 3 h, were rinsed twice with culture medium containing 3% serum, then placed in MLN-15 and subjected to X-ray irradiation. Kinetics assessment of the sensitivity of A549 cells to chemicals and radiation was performed using a colony formation method and corrected based on the plating efficiency of the control (i.e. 80-90%). The average colony multiplicity was <1.1. The D 0 value, adopted as the criterion of cellular radiosensitivity or chemosensitivity, represented the doses required to reduce survival by 1/e in the exponentially regressing portion of the survival curves, i.e. the linear portions of the doses (or treatment period) -surviving fractions curve plotted on semilogarithmic section paper. Fractionated radiotherapy was carried out for 1-4 fractions at 2 Gy for 24 h intervals at 37˚C.
Analysis of apoptosis and necrosis.
The induction of apoptosis was analyzed at 48 and 72 h after treatment with 0.02 μg/ml AMROH for 4 h, X-ray irradiation at 6 Gy, and a combination of both. Trypsinized cells were placed in MLN-15 to stop trypsinization, then rinsed with PBS(-), fixed overnight in 1% glutaraldehyde (Nakalai Tesque, Kyoto, Japan), and placed in PBS(-). For observation, cells were stained with 0.2 mM Höchst 33342; Bisbenzimide H33342 Fluorochrome, Trihydrochloride (Calbiochem, Merck KGoA, Darmstadt, Germany) and analyzed under a fluorescence microscope (Nikon Eclipse E600, Nikon Co. Ltd., Tokyo, Japan). A total of 1000 cells were counted and the percentage of typical apoptotic cells was calculated. The induction of necrosis was also determined after the treatments described above. After double-staining the cells with acridine orange (Sigma-Aldrich Co. St. Louis, USA) and ethidium bromide (Nacalai Tesque Inc.) (AO/EB) (44), they were observed in real-time under a fluorescence microscope and the percentage of rubinus necrotic cells was calculated.
Results

Survival of A549 cells following X-ray irradiation.
As for the radiosensitivity of A549 cells, the D 0 value, which was the reciprocal of the slope of the survival curve in the exponential phase, was 2.0 Gy following irradiation. As in the case of Elkind recovery associated with low-dose radiotherapy, the SLDR, which is seen as a curved shoulder, was identified during the early stages following irradiation. The D q value reflecting cellular capacity for SLDR, was 1.7 Gy as shown in Figs. 1 and 2 .
Effects of AMR and AMROH with X-ray irradiation. Using A549 cells, the radio-enhancement effects of AMR and AMROH were investigated based on the survival curves drawn following irradiation and AMROH combination therapy as shown in Figs. 1 and 2 . The survival curve of the cells that received irradiation alone elicited a shoulder, indicating the repair of SLD, whereas the curve for those cells following sequential combined treatment with AMR or AMROH was reduced. In other words, SLDR associated with low doses of radiation was blocked by AMR or AMROH. Further, the survival curve slopes in the exponential phase for irradiation alone and combination therapy with AMR or AMROH were parallel, i.e. administration of AMR or AMROH prior to irradiation resulted in additive radio-enhancement effects. The combined treatment dose to accomplish cytocidal effects as well as irradiation alone was reduced by one-third. Also the radio-enhancement effects of 4 topoisomerase II inhibitors in isotoxic doses, ADM (0.02 μg/ml), VP-16 (2.0 μg/ml), AMR (2.5 μg/ml), and AMROH (0.02 μg/ml) with X-ray irradiation at 2 or 8 Gy were compared with the results shown in Table I . The effects of the 4 different chemicals as estimated by their D 0 values were comparable to the markedly enhanced effects of X-ray irradiation.
Fractionated X-ray irradiation with AMR and AMROH.
Fractionated irradiation of 2 Gy per fraction was carried out 4 times with 24 h intervals for a total dose of 8 Gy using A549 cells, as shown in Figs. 3 and 4 . Although the survival curve of irradiation alone exhibited radio-resistance due to SLDR, the shoulder-shaped portion of the curve was inhibited by simultaneous or sequential combined treatments with AMR or AMROH for 3 h prior to irradiation. Further, the survival curve obtained the same slope with continuous irradiation. The surviving fractions following 8 Gy of irradiation showed the following results: single fractionated irradiation, 0.19; single continued irradiation, 0.047; irradiation combined with AMR, 0.0093; and irradiation combined with AMROH, 0.0068 (Figs. 3 and 4) . Both AMR and AMROH inhibited SLDR of the cells following continued irradiation, and fractionated Table I . Comparison of radio-enhancement by four topoisomerase II inhibitors. 
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The radio-enhancement effects of radiotherapy with the 4 DNA topoisomerase II inhibitors, AMR, AMROH, ADM and VP-16, were compared by D 0 value. A549 cells were treated with each agent at an isotoxic dose (AMR, 2.5 μg/ml; AMROH, 0.02 μg /ml; ADM, 0.02 μg/ml; VP-16, 2.0 μg/ml) for 3 h, followed by irradiation in the combined treatment protocol, respectively.
irradiation at 8 Gy combined with AMR or AMROH had estimated cytocidal effects in a range of 20-28 times greater in comparison with single fractionated irradiation at the same dose.
Effects on apoptosis induction. The radio-enhancement effects of AMROH on A549 cells were investigated based on the induction of apoptosis, as shown in Fig. 5 . Following exposure to AMROH for 4 h, X-ray irradiation at 6 Gy, and a combination of both, the cells were harvested after 48 and 72 h of incubation and fixed with glutaraldehyde. The fixed cells were then stained with Höchst 33342 solution and cellular morphology was observed under a fluorescence microscope in order to determine the percentage of apoptotic cells. At 48 and 72 h after treatment with AMROH alone, the incidence of apoptosis was 0.9% and 0.88%, respectively, while it was 1.2% and 0.71%, respectively for X-ray irradiation alone, and 1.4% and 1.5%, respectively for the combination therapy.
Effects on necrosis induction. As in the case with apoptosis, the radio-enhancement effects of AMROH on A549 cells were investigated in regard to the induction of necrosis, as shown in Fig. 6 . The incidence of necrotic cells following AMROH treatment, X-ray irradiation, and a combination of both was investigated using AO/EB double staining at 48 and 72 h after treatment. The incidence of necrosis at 48 and 72 h after treatment with AMROH alone was 2.4% and 4.3%, respectively, while it was 2.6% and 3.66%, respectively, following X-rays alone, and 5.0% and 6.0%, respectively after combined treatment (Fig. 6) . 
Discussion
In the present study, the radio-enhancement effects of the topoisomerase II inhibitor AMR and its metabolite AMROH toward the mechanisms of modification in human lung adenocarcinoma A549 cells were investigated.
Profile of AMR. The anthracycline derivative AMR and its active metabolite AMROH are synthesized antitumor agents and have been shown to be DNA topoisomerase II inhibitors (5, 6) . It has been reported that DNA topoisomerase II is vital for essential biological reactions, such as replication, transcription, and genetic recombination (45, 46) , and Nelson et al reported that mAMSA [4'-(9-acridinylamino) methane sulfonm-anisidide], an antitumor agent, inhibited topoisomerase II in mammals (47) . Therefore, topoisomerase II inhibitors are effective anticancer agents, because topoisomerase II inactivation and inhibition have severe effects on cell survival (48, 49) .
Effects on radiation. Following X-ray irradiation alone, the A549 cells were found to be radioresistant with a D 0 value of 12 Gy, as shown in Figs. 1 and 2 . When the cells were treated with AMR or AMROH prior to irradiation in vitro, the SLDR seen during the early stages after irradiation was inhibited. The so-called shoulder-shape portion from irradiation mainly was diminished by sequential combined treatment with AMR or AMROH, as both AMR and AMROH enhanced radiosensitivity in an additive manner ( Figs. 1 and 2) . The dose required to achieve 10% survival (surviving fraction at 0.1) with irradiation alone was approximately 8 Gy, while that with the combination therapy was approximately 2 Gy. Comparable results were obtained with approximately one-fourth of the dose by combining radiotherapy with AMR or AMROH, which is a beneficial finding for multidisciplinary anticancer therapy.
We previously investigated the abilities of various chemicals, including adriamycin (doxorubicin), bleomycin, cisplatin, and AMR (or AMROH) to modify the effects of hyperthermia using different cells at kinetic and molecular levels (23, (50) (51) (52) (53) . The effects of AMR, AMROH, ADM (54) , and VP-16 (55) , which target DNA metabolism, on the radiosensitivity of A549 cells are compared in Table I . When A549 cells were treated with isotoxic doses of AMR, AMROH, ADM or VP-16 for 3 h and then sequentially subjected to ionizing radiation of 2-8 Gy, comparable degrees of enhancement were noted. These findings clarify that all topoisomerase II inhibitors increase the radiosensitivity of A549 cells. Among the different types of radiotherapy that target the DNA of oncogenes, radiochemotherapy has a direct enhancement effect, because DNA damage increases synergistically in situations in which the drugs and X-ray irradiation simultaneously act on DNA.
Fractionated radiotherapy. Combined radiotherapy with AMR or AMROH from 1 to 4 times the level of fractionated irradiation of 2 Gy for 24-h intervals using A549 cells in vitro was carried out, as shown in Figs. 3 and 4 . As a result, the radiosensitivity of sequential combined treatment with AMR or AMROH was enhanced by reducing SLDR for intervals with fractionated irradiation with X-rays alone and the survival curve became parallel with that of continuous irradiation. Namely, when the cells were treated with AMR or AMROH prior to fractionated irradiation, the cytocidal effect at 8 Gy on the survival curve was approximately 30 times greater than that with irradiation alone. In radiotherapy, if the curative dose exceeds the tolerated dose of normal tissue, irradiation cannot be given without side effects in normal tissue. However, if it is possible to reduce the radiosensitivity of normal tissue or to increase the radiosensitivity of the tumor, radiotherapy can be performed with reduced side effects. It is generally known that if drugs are used to inhibit the activities of enzyme or the repair of DNA damage, the cells experience interphase cell death without cell division or mitotic cell death after several divisions. When irradiated tumor cells have repaired the damage, the radio-enhancement effects are likely to lead to greater damage with chemotherapy drugs or the repair is inhibited. We found that AMR and AMROH were able to reduce SLDR, thus they are expected to significantly increase the radio-enhancement effects of fractionated irradiation. In the present study, we found that AMR was a candidate anticancer therapeutic agent for non-small cancer cells, as the radio-enhancement effects of AMR were shown from a kinetics point of view.
Induction of apoptosis and necrosis. We also investigated the kinetics of apoptosis during the induction periods following AMROH administration, X-ray irradiation and a combination of both. The induction of apoptosis following irradiation of 6 Gy with 0.02 μg/ml of AMROH for 4 h increased slightly with time, though there was no significant increase following such sequential combination therapy. The induction of necrosis following radiotherapy also increased with time and there was a significant increase in the induction of necrosis after 4 h of exposure to AMROH followed by X-ray irradiation. The p53-mediated apoptosis has been thought to be cell cycle dependent (24, 56) . We have reported that a cell phase response of A549 cells with wtp53 to AMR or AMROH was not seen regardless of the agent concentrations (13) . Those findings suggested that AMR and AMROH directly inhibit DNA topoisomerase II activities without affecting the p53 cascade, in spite of the wild type. AMR and AMROH were also shown to dynamically enhance the radiosensitivity of A549 cells. Thus, for multidisciplinary anticancer therapy, the antitumor effects of radiotherapy can be improved by administering AMR or its metabolite AMROH.
